

Persistent Systems

BSE SENSEX
77,094

S&P CNX
24,103

CMP: INR4,861

TP: INR6,200(+28%)

Buy



Stock Info

Bloomberg	PSYS IN
Equity Shares (m)	158
M.Cap.(INRb)/(USD\$b)	766.7 / 8.1
52-Week Range (INR)	6599 / 4449
1, 6, 12 Rel. Per (%)	-4/-18/-16
12M Avg Val (INR M)	3332
Free float (%)	69.7

Financials & Valuations (INR b)

Y/E Mar	FY26	FY27E	FY28E
Sales	147.5	178.3	209.7
EBIT Margin (%)	16.2	16.7	16.8
Adj. PAT	19.3	23.7	27.9
Adj. EPS (INR)	123.3	150.1	177.1
EPS Gr.(%)	36.7	21.7	18.0
BV/Sh.(INR)	503.6	591.3	698.3

Ratios

RoE (%)	27.3	27.7	27.7
RoCE (%)	24.6	24.6	24.6
Payout (%)	40.0	40.0	40.0

Valuations


P/E (x)	39.4	32.4	27.4
P/BV (x)	9.7	8.2	7.0
EV/EBITDA (x)	25.9	21.0	17.5
Div. Yield (%)	1.0	1.2	1.5

Shareholding Pattern (%)

As On	Mar-26	Dec-25	Mar-25
Promoter	30.3	30.3	30.7
DII	30.5	29.8	26.9
FII	23.1	23.7	25.2
Others	16.2	16.2	17.3

FII includes depository receipts

Stock's performance (one-year)



Takeaways from our meeting with the CFO

Core growth intact; AI/license monetization real but evolving; Europe M&A likely

- We met with the CFO of Persistent Systems (PSYS), Mr. Vinit Teredesai, and the leadership team. Key points from our meeting: 1) We expect BFSI to be the strongest vertical and could lead growth in FY27E, followed by healthcare and hi-tech, although SaaS remains relatively softer, 2) AI and license revenue, coupled with Sasva and iAura, continue to provide PSYS with a competitive edge over the market for now, 3) Margins are expected to operate within a narrow range, and 4) M&A strategy is likely to focus on Europe and diversification.
- Despite turbulences, we expect PSYS to achieve its USD2b run rate target by 4QFY27E, and believe the core growth thesis remains intact. We value PSYS at 34x FY28E EPS. Reiterate BUY with a TP of INR6,200.

BFSI to lead in FY27E, followed by Healthcare and Hi-Tech

- BFSI remains the strongest vertical and is expected to lead growth in FY27E, driven by new logo additions and increased wallet share from large, systemically important banks (refer to Exhibit 5).
- Wealth management, brokerage, and insurance are broadening the client base within the vertical. **Healthcare remains structurally supportive, although client-specific issues could result in some short-term turbulence**, with growth from other healthcare clients partially offsetting the impact.
- **Hi-tech is bifurcated: CMT and select enterprise clients are doing well**, while hardware SaaS and PE-backed tech remain soft, in line with macros and AI impact.

AI and license revenue: Giving PSYS an edge for now

- The **USD28m quarterly AI/license line is a mix of three components**: the legacy SaaS stream, the older Accelerate product, and a newer license tied to recent engagements, with the split varying based on the timing of license purchases (refer to Exhibit 6).
- Management was explicit that PSYS is not pivoting to a pure-license model. Rather, license sales serve as proof of capability to unlock wider enterprise deployment. **Sasva and iAura provide a productized toolkit that, for now, keeps PSYS ahead of most peers.**
- The company continues to see AI monetization move beyond proofs-of-concept, **particularly in data modernization and enterprise data-layer transformation programs**, where AI is helping customers accelerate migration and modernization efforts.
- **Commercial structures remain flexible, with customers adopting a mix of upfront licensing, premium pricing, and outcome-based implementation models.** Management indicated that the objective is not maximizing near-term license revenue, but expanding into broader enterprise-wide adoption over time.

Abhishek Pathak - Research Analyst (Abhishek.Pathak@MotilalOswal.com)

Keval Bhagat - Research Analyst(Keval.Bhagat@MotilalOswal.com)

Investors are advised to refer through important disclosures made at the last page of the Research Report.

Motilal Oswal research is available on www.motilaloswal.com/Institutional-Equities, Bloomberg, Thomson Reuters, Factset and S&P Capital.

Margins: Disciplined band, growth is the priority

- **PSYS has guided for margins in the 16-17% operating band** and considers the target achieved. Management's posture is clear: growth reinvestment takes precedence beyond 17%.
- **Productivity metrics — revenue per employee and cost per employee in USD terms — are the preferred health indicators over headcount alone.** At ~USD1.8b annualized revenue with the USD2b milestone in reach, we see limited margin contraction risk; the band is conservative enough to absorb reinvestment without a structural reset.

M&A: Europe, capability depth, and meaningful scale


- **M&A remains active, and Europe is the primary target: North America accounts for ~80% of revenue, and management aims to cut this concentration.** The ideal target brings nearshore delivery scale, and vertical diversification along with engineering capability.
- Management indicated that acquisition valuations have become materially more reasonable versus prior years, creating a more favorable environment to pursue strategically relevant assets. We believe this improves the likelihood of the company executing larger and more meaningful acquisitions. **The focus remains on platform engineering, product engineering, and deep domain expertise** rather than staffing-led businesses.
- In our view, Europe is attractive not only for revenue diversification but also for expanding nearshore delivery capacity. **Preferred acquisition areas include BFSI, healthcare, manufacturing, utilities, and consumer-facing industries.**

Valuation and view

- **We believe the core growth thesis remains intact,** supported by continued BFSI momentum, differentiated AI and platform-led offerings, and a disciplined M&A strategy aimed at expanding its European presence and reducing geographic concentration.
- While AI/license revenues may remain volatile on a quarterly basis, they continue to strengthen PSYS's positioning in large enterprise transformation programs.
- **We model ~16% USD revenue CAGR over FY26-28E,** supported by a combination of organic growth and selective acquisitions. Along with gradual margin expansion, this translates into ~20-22% EPS CAGR, still among the stronger growth profiles in mid-tier IT. **We continue to value PSYS at 34x FY28E EPS and reiterate BUY with a TP of INR 6,200.**


Story in charts

Exhibit 1: BTB rose to 1.6x; TCV stood at USD 601m




Source: Company, MOFSL

Exhibit 2: BFSI remains the strongest vertical and is expected to lead growth in FY27E, driven by new logo additions




Source: Company, MOFSL

Exhibit 3: License revenue at a USD28m quarterly run rate: providing PSYS with an edge for now




Source: Company, MOFSL

Exhibit 4: Delivered 3.4% QoQ CC growth in 4QFY26, continuing to outpace most peers




Source: Company, MOFSL

Exhibit 5: Margins contracted 40bp QoQ in 4Q




Source: Company, MOFSL

Exhibit 6: Utilization declined 40bp to 88% in 4QFY26



Source: Company, MOFSL

Exhibit 7: Attrition rate declined 50bp QoQ



Source: Company, MOFSL

Exhibit 8: Productivity metrics - revenue per employee in USD terms - are preferred indicators of business health over headcount alone and have shown steady improvement in realizations YoY



Source: Company, MOFSL

Financials and valuations

Income Statement							(INR m)
Y/E March	2022	2023	2024	2025	2026	2027E	2028E
Sales	57,107	83,506	98,216	1,19,387	1,47,485	1,78,268	2,09,688
Change (%)	36.4	46.2	17.6	21.6	23.5	20.9	17.6
Cost of Goods Sold	37,895	55,315	65,231	78,740	94,874	1,14,787	1,34,871
Gross Profit	19,212	28,191	32,985	40,647	52,610	63,481	74,817
Selling Expenses	9,556	12,999	15,742	20,066	24,656	29,322	34,599
EBITDA	9,656	15,191	17,243	20,581	27,955	34,159	40,219
% of Net Sales	16.9	18.2	17.6	17.2	19.0	19.2	19.2
Depreciation	1,660	2,719	3,094	3,069	4,030	4,457	5,033
EBIT	7,996	12,472	14,149	17,512	23,925	29,702	35,186
% of Net Sales	14.0	14.9	14.4	14.7	16.2	16.7	16.8
Other Income	1,321	233	813	710	1,078	1,248	1,468
PBT	9,317	12,705	14,962	18,222	25,002	30,950	36,654
Tax	2,339	3,198	3,541	4,222	5,683	7,273	8,710
Rate (%)	25.1	25.2	23.7	23.2	22.7	23.5	23.8
Extraordinary Item	75	297	486	0	668	0	0
Adjusted PAT	6,904	9,211	10,935	14,001	18,651	23,677	27,944
Change (%)	53.2	33.4	18.7	28.0	33.2	26.9	18.0

Balance Sheet							(INR m)
Y/E March	2022	2023	2024	2025	2026	2027E	2028E
Share Capital	764	764	770	779	789	789	789
Other Reserves	32,918	38,887	48,807	62,411	77,590	91,796	1,08,563
Net Worth	33,682	39,651	49,577	63,191	78,379	92,585	1,09,351
Loans	4,889	4,947	99	-	-	-	-
Other liabilities	1,360	2,013	2,218	2,848	6,144	7,427	8,736
Capital Employed	39,931	46,610	51,894	66,038	84,523	1,00,011	1,18,087
Gross Block	27,391	33,914	32,079	36,920	42,839	48,339	53,839
Less : Depreciation	14,965	17,684	20,777	23,847	27,876	32,333	37,366
Net Block	4,276	7,058	6,727	8,150	9,441	10,484	10,951
CWIP	1,071	161	335	42	107	107	107
Intangibles	11,060	16,355	15,488	17,261	19,119	19,119	19,119
Investments	3,878	4,516	5,539	6,415	7,001	7,001	7,001
Deferred Tax Assets	1,123	1,129	1,360	2,024	3,460	4,182	4,919
Other	4,394	1,792	3,056	3,215	3,665	4,429	5,210
Current Assets	28,339	35,179	41,232	50,260	70,973	88,697	1,09,269
Debtors	9,484	15,705	16,761	18,478	21,332	25,397	29,873
Investments	10,514	6,242	6,330	6,899	22,665	13,153	15,653
Cash & BB	2,978	4,670	6,625	6,744	10,749	30,533	40,672
Loans & Advances	16	-	-	-	-	-	-
Other Current Assets	5,347	8,562	11,515	18,139	16,227	19,614	23,071
Current Liab. & Prov	14,210	19,581	21,842	21,328	29,243	34,009	38,491
Trade payables	4,299	5,689	8,139	8,886	11,342	14,164	16,660
Other Liabilities	5,961	9,243	10,372	8,413	9,058	9,157	9,258
Provisions	3,950	4,649	3,331	4,029	8,843	10,689	12,573
Net Current Assets	14,130	15,598	19,390	28,932	41,730	54,688	70,778
Application of Funds	39,931	46,610	51,894	66,038	84,523	1,00,011	1,18,086

Financials and valuations

Ratios

Y/E March	2022	2023	2024	2025	2026	2027E	2028E
EPS	45.7	62.5	75.1	90.2	123.3	150.1	177.1
Cash EPS	56.5	80.4	95.4	110.0	149.0	178.3	209.0
Book Value	220.4	260.7	325.9	411.9	503.6	591.3	698.3
DPS	15.5	25.0	26.0	35.0	49.3	60.0	70.9
Payout %	33.9	40.0	34.6	38.8	40.0	40.0	40.0
Valuation (x)							
P/E	106.5	77.8	64.7	53.9	39.4	32.4	27.4
Cash P/E	86.0	60.5	50.9	44.2	32.6	27.3	23.3
EV/EBITDA	76.0	48.3	42.1	35.6	25.9	21.0	17.5
EV/Sales	12.9	8.8	7.4	6.1	4.9	4.0	3.4
Price/Book Value	22.1	18.6	14.9	11.8	9.7	8.2	7.0
Dividend Yield (%)	0.3	0.5	0.5	0.7	1.0	1.2	1.5
Profitability Ratios (%)							
RoE	22.6	25.9	25.6	24.8	27.3	27.7	27.7
RoCE	17.4	21.6	21.9	22.8	24.6	24.6	24.6
Turnover Ratios							
Debtors (Days)	61	69	62	56	53	52	52
Asset Turnover (x)	15.2	14.7	14.2	16.1	16.8	17.9	19.6

Cash Flow Statement

Y/E March	2022	2023	2024	2025	2026	2027E	2028E
CF from Operations	8,857	13,935	14,265	17,803	23,458	28,134	32,977
Chg. in Working Capital	-407	-4,377	-2,052	-6,233	-5,788	9,122	-3,661
Net Operating CF	8,450	9,558	12,213	11,569	17,670	37,256	29,316
Net Purchase of FA	-3,808	-4,290	-2,710	-1,931	-1,952	-5,500	-5,500
Free Cash Flow	4,642	5,268	9,503	9,638	15,718	31,756	23,816
Net Purchase of Invest.	-5,965	76	-1,985	-2,414	-4,147	-2,500	-2,500
Net Cash from Inv.	-9,773	-4,213	-4,695	-4,344	-6,099	-8,000	-8,000
Issue of shares	0	0	1,608	0	499	0	0
Proceeds from LTB/STB	3,810	-1,059	-3,461	-1,309	-1,798	0	0
Dividend Payments	-1,987	-2,981	-4,084	-4,973	-6,183	-9,471	-11,178
Net CF from Finan.	1,823	-4,039	-5,937	-6,282	-7,482	-9,471	-11,178
Net Cash Flow	499	1,305	1,581	943	4,090	19,785	10,138
Exchange difference	59	387	374	-824	-85	0	0
Opening Cash Balance	2,420	2,979	4,671	6,626	6,745	10,749	30,534
Closing CashBalance	2,979	4,671	6,626	6,745	10,749	30,534	40,673

(INR m)

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Explanation of Investment Rating	
Investment Rating	Expected return (over 12-month)
BUY	>=15%
SELL	< - 10%
NEUTRAL	< - 10 % to 15%
UNDER REVIEW	Rating may undergo a change
NOT RATED	We have forward looking estimates for the stock but we refrain from assigning recommendation

*In case the recommendation given by the Research Analyst is inconsistent with the investment rating legend for a continuous period of 30 days, the Research Analyst shall be within following 30 days take appropriate measures to make the recommendation consistent with the investment rating legend.

Disclosures

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

Motilal Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst having registration no. INH000000412 and BSE enlistment no. 5028. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. MOFSL is a listed public company, the details in respect of which are available on www.motilaloswal.com. MOFSL is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE), Multi Commodity Exchange of India Limited (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) National Securities Depository Limited (NSDL), NERL, COMRIS and CCRL and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products and Insurance Regulatory & Development Authority of India (IRDA) as Corporate Agent for insurance products and is a member of Association of Portfolio Managers in India (APMI) for distribution of PMS products. Details of associate entities of Motilal Oswal Financial Services Ltd. are available on the website at <http://onlinereports.motilaloswal.com/Dormant/documents/Associate%20Details.pdf>

MOFSL and its associate company(ies), their directors and Research Analyst and their relatives may; (a) from time to time, have a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

MOFSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. Details of pending Enquiry Proceedings of Motilal Oswal Financial Services Limited are available on the website at <https://galaxy.motilaloswal.com/ResearchAnalyst/PublishViewLitigation.aspx>. As per Regulatory requirements, Research Audit Report is uploaded on www.motilaloswal.com > MOFSL-Important Links > MOFSL Research Analyst Compliance Audit Report.

A graph of daily closing prices of securities is available at www.nseindia.com, www.bseindia.com. Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MOFSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOFSL research activity and therefore it can have an independent view with regards to Subject Company for which Research Team have expressed their views.

Regional Disclosures (outside India)

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL & its group companies to registration or licensing requirements within such jurisdictions.

For Hong Kong:

This report is distributed in Hong Kong by Motilal Oswal capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Securities (SEBI Reg. No. INH000000412) has an agreement with Motilal Oswal capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

For U.S.

Motilal Oswal Financial Services Limited (MOFSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the "1934 act") and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts"), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOFSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement.

The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

For Singapore

In Singapore, this report is being distributed by Motilal Oswal Capital Markets (Singapore) Pte. Ltd. ("MOCMSPL") (UEN 201129401Z), which is a holder of a capital markets services license and an exempt financial adviser in Singapore. This report is distributed solely to persons who (a) qualify as "institutional investors" as defined in section 4A(1)(c) of the Securities and Futures Act of Singapore ("SFA") or (b) are considered "accredited investors" as defined in section 2(1) of the Financial Advisers Regulations of Singapore read with section 4A(1)(a) of the SFA. Accordingly, if a recipient is neither an "institutional investor" nor an "accredited investor", they must immediately discontinue any use of this Report and inform MOCMSPL .

In respect of any matter arising from or in connection with the research you could contact the following representatives of MOCMSPL. In case of grievances for any of the services rendered by MOCMSPL write to grievances@motilaloswal.com.

Nainesh Rajani

Email: nainesh.rajani@motilaloswal.com

Contact: (+65) 8328 0276

Specific Disclosures

- Research Analyst and/or his/her relatives do not have a financial interest in the subject company(ies), as they do not have equity holdings in the subject company(ies). MOFSL has financial interest in the subject company(ies) at the end of the week immediately preceding the date of publication of the Research Report: Yes.
Nature of Financial interest is holding equity shares or derivatives of the subject company
- Research Analyst and/or his/her relatives do not have actual/beneficial ownership of 1% or more securities in the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report.
MOFSL has actual/beneficial ownership of 1% or more securities of the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report:No
- Research Analyst and/or his/her relatives have not received compensation/other benefits from the subject company(ies) in the past 12 months.
MOFSL may have received compensation from the subject company(ies) in the past 12 months.
- Research Analyst and/or his/her relatives do not have material conflict of interest in the subject company at the time of publication of research report.
MOFSL does not have material conflict of interest in the subject company at the time of publication of research report.
- Research Analyst has not served as an officer, director or employee of subject company(ies).
- MOFSL has not acted as a manager or co-manager of public offering of securities of the subject company in past 12 months.
- MOFSL has not received compensation for investment banking /merchant banking/brokerage services from the subject company(ies) in the past 12 months.
- MOFSL may have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company(ies) in the past 12 months.
- MOFSL may have received compensation or other benefits from the subject company(ies) or third party in connection with the research report.
- MOFSL has not engaged in market making activity for the subject company.

The associates of MOFSL may have:

- financial interest in the subject company
 - actual/beneficial ownership of 1% or more securities in the subject company at the end of the month immediately preceding the date of publication of the Research Report or date of the public appearance.
 - received compensation/other benefits from the subject company in the past 12 months
 - any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.
 - acted as a manager or co-manager of public offering of securities of the subject company in past 12 months
 - be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies)
 - received compensation from the subject company in the past 12 months for investment banking / merchant banking / brokerage services or from other than said services.
 - Served subject company as its clients during twelve months preceding the date of distribution of the research report.
- The associates of MOFSL has not received any compensation or other benefits from third party in connection with the research report
 Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, It does not consider demat accounts which are opened in name of MOFSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures.

Analyst Certification

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

Terms & Conditions:

This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report.

Disclaimer:

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alternations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, nor its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOFSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays.

This report is meant for the clients of Motalal Oswal only.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI, enlistment as RA with Exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors

Registered Office Address: Motalal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022 - 71934200 / 71934263; www.motalaloswal.com. Correspondence Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad (West), Mumbai- 400 064. Tel No: 022 71881000. Details of Compliance Officer: Neeraj Agarwal, Email Id: na@motalaloswal.com, Contact No.:022-40548085.

Grievance Redressal Cell:

Contact Person	Contact No.	Email ID
Ms. Hemangi Date	022 40548000 / 022 67490600	query@motalaloswal.com
Ms. Kumud Upadhyay	022 40548082	servicehead@motalaloswal.com
Mr. Ajay Menon	022 40548083	am@motalaloswal.com
Mr. Neeraj Agarwal	022 40548085	na@motalaloswal.com
Mr. Siddhartha Khemka	022 50362452	po.research@motalaloswal.com

Registration details of group entities.: Motalal Oswal Financial Services Ltd. (MOFSL): INZ000158836 (BSE/NSE/MCX/NCDX); CDSL and NSDL: IN-DP-16-2015; Research Analyst: INH000000412, BSE enlistment no. 5028, AMFI registered Mutual Fund Distributor and SIF Distributor: ARN : 146822. IRDA Corporate Agent – CA0579, APMI: APRN00233. Motalal Oswal Financial Services Ltd. is a distributor of Mutual Funds, PMS, Fixed Deposit, Insurance, Bond, NCDs and IPO products.

Customer having any query/feedback/ clarification may write to query@motalaloswal.com. In case of grievances for any of the services rendered by Motalal Oswal Financial Services Limited (MOFSL) write to grievances@motalaloswal.com, for DP to dpgrievances@motalaloswal.com.